Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

For decades, gynecologic cancer treatment has used aggressive surgical intervention and chemotherapy. These methods often ...

CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.